论文部分内容阅读
目的:观察盐酸川芎嗪注射液联合胰岛素对2型糖尿病肾病患者临床症状和肾功能的影响。方法:选取本院102例2型糖尿病肾病患者作为研究对象,采用随机数字表法分为观察组与对照组各51例。对照组采用重组人胰岛素治疗,观察组在对照组治疗基础上加用盐酸川芎嗪注射液治疗。观察2组临床疗效,比较2组治疗前和治疗3月后的临床症状积分,以及治疗前1周、治疗6月后的肾功能,并观察2组治疗期间的不良反应发生情况。结果:治疗总有效率观察组为88.24%,高于对照组的66.67%,2组比较,差异有统计学意义(P<0.05)。治疗后,2组各项临床症状积分均下降(P<0.05),观察组各项临床症状积分均低于对照组(P<0.05)。治疗前,2组24 h尿蛋白定量、血肌酐(SCr)、尿素氮(BUN)及尿红细胞含量比较,差异均无统计学意义(P>0.05)。治疗后,2组各项肾功能指标含量较治疗前下降(P<0.05),观察组的各项肾功能指标含量均低于对照组(P<0.05)。结论:盐酸川芎嗪注射液联合胰岛素治疗2型糖尿病肾病,可有效改善患者的临床症状,降低24 h尿蛋白定量、SCr、BUN及尿红细胞的含量,是安全可靠的治疗方案。
Objective: To observe the effects of ligustrazine hydrochloride combined with insulin on clinical symptoms and renal function in patients with type 2 diabetic nephropathy. Methods: A total of 102 patients with type 2 diabetic nephropathy in our hospital were selected as study subjects and divided into observation group and control group by random number table. The control group was treated with recombinant human insulin. The observation group was treated with ligustrazine hydrochloride injection on the basis of the control group. The clinical efficacy of the two groups were observed. The clinical symptom scores before and after 3 months of treatment were compared between two groups. The renal function of the two groups before treatment and after 6 months of treatment were compared. The occurrence of adverse reactions in the two groups were observed. Results: The total effective rate in the observation group was 88.24%, which was higher than that in the control group (66.67%). There was significant difference between the two groups (P <0.05). After treatment, the scores of clinical symptoms decreased in both groups (P <0.05), and the scores of clinical symptoms in the observation group were lower than those in the control group (P <0.05). Before treatment, 24-hour urinary protein excretion, serum creatinine (SCr), blood urea nitrogen (BUN) and urine red blood cells in two groups had no significant difference (P> 0.05). After treatment, the content of each renal function index in two groups decreased compared with that before treatment (P <0.05), and all the indexes of renal function in the observation group were lower than those in the control group (P <0.05). CONCLUSION: Ligustrazine hydrochloride injection combined with insulin in the treatment of type 2 diabetic nephropathy can effectively improve the clinical symptoms, reduce 24 h proteinuria, SCr, BUN and urinary red blood cells, which is a safe and reliable treatment.